Ipsen Closes Purchase of Potravitug Developer Memo Therapeutics

MT Newswires · 4d ago
01:28 AM EDT, 07/22/2026 (MT Newswires) -- Ipsen (IPN.PA) said Wednesday it completed the acquisition of late-stage biotechnology company Memo Therapeutics. The acquired company is focused on developing potravitug, a first-in-class monoclonal antibody preventing BK polyomavirus reactivation in kidney transplant recipients. The French biopharmaceutical company previously said the transaction has a total potential consideration of over 700 million euros.